Results 41 to 50 of about 16,133 (222)

Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms [PDF]

, 2012
BACKGROUND AND PURPOSE Widespread resistance to antimalarial drugs requires combination therapies with increasing risk of pharmacokinetic drugdrug interactions.
Alexander, Arnold, Asimus, Auerbach, Auerbach, Baes, Berman, Blättler, Burk, Burk, di Masi, Dring, Elsherbiny, Faucette, Gautam, Giao, Grace, Halgren, Hesse, Hoffart, Honda, Huey, Hustert, Jyrkkärinne, Kawamoto, Kerb, Khoo, Krey, Kyle, Lee, Maglich, Moore, Morris, Navaratnam, Nussler, Pan, Pissios, Ross, Sanner, Simonsson, Skinner-Adams, Svensson, Svärd, Wang, Ward, White, WHO, WHO, Windshügel, Wolbold, Xu, Zhang   +51 more
core   +1 more source

Role of CYP2B6 in Stereoselective Human Methadone Metabolism [PDF]

Anesthesiology, 2008
Background Metabolism and clearance of racemic methadone are stereoselective and highly variable, yet the mechanism remains largely unknown. Initial in vitro studies attributed methadone metabolism to cytochrome P4503A4 (CYP3A4). CYP3A4 was also assumed responsible for methadone clearance in vivo.
Rheem A, Totah, Pamela, Sheffels, Toni, Roberts, Dale, Whittington, Kenneth, Thummel, Evan D, Kharasch   +5 more
openaire   +2 more sources

Variants in the CYP2B6 3′UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs [PDF]

, 2017
CYP2B6*6 and CYP2B6*18 are the most clinically important variants causing reduced CYP2B6 protein expression and activity. However, these variants do not account for all variability in CYP2B6 activity.
Burgess, Kimberly S., Desta, Zeruesenay, Gaedigk, Andrea, Gaedigk, Roger, Gufford, Brandon T., Ipe, Joseph, Liu, Yunlong, Lu, Jessica, Metzger, Ingrid F., Pearce, Robin, Skaar, Todd C., Swart, Marelize, Thong, Nancy   +12 more
core   +1 more source

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects [PDF]

, 2017
In vitro studies showed that CYP2C19, CYP2B6, and CYP1A2 contribute to the metabolism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to 3,4-methylenedioxyamphetamine (MDA).
Liechti, Matthias E., Meyer Zu Schwabedissen, Henriette E., Prestin, Katharina, Schmid, Yasmin, Vizeli, Patrick   +4 more
core   +1 more source

CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon

Infection, Genetics and Evolution, 2015
The prescription of patients' tailored anti-infectious treatments is the ultimate goal of pharmacogenetics/genomics applied to antimicrobial treatments, providing a basis for personalized medicine. Despite the efforts to screen Africans for alleles underlying defective metabolism for a panel of different drugs, still more research is necessary to ...
RUSSO, Gianluca, Sobze, Martin Sanou, Mayaka, George Bouting, Muthoga, Charles Waithaka, Tawe, Leabaneng, Martinelli, Axel, ROMANO, Rita, VULLO, Vincenzo, Paganotti, Giacomo Maria   +8 more
openaire   +3 more sources

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Agúndez, José Augusto, García-Martín, Elena, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge   +18 more
core   +6 more sources

HIV treatment outcomes in Uganda : the impact of baseline characteristics and variability in pharmacokinetics and pharmacogenetics of antiretroviral drugs [PDF]

, 2013
Guidelines specify criteria for initiation and monitoring of antiretroviral treatment (ART), including options for first line regimens. Immunological progress remains a widely used form of HIV/ART monitoring and efavirenz, a preferred first line ...
Nanzigu, Sarah
core   +1 more source

Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo [PDF]

Drug Metabolism and Disposition, 2012
The mechanism by which CYP2B6*6 allele alters drug metabolism in vitro and in vivo is not fully understood. To test the hypothesis that altered substrate binding and/or catalytic properties contribute to its functional consequences, efavirenz 8-hydroxylation and bupropion 4-hydroxylation were determined in CYP2B6.1 and CYP2B6.6 proteins expressed ...
Cong, Xu, Evan T, Ogburn, Yingying, Guo, Zeruesenay, Desta   +3 more
openaire   +2 more sources

Pharmacokinetic and Pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients: Implication for optimization of TB-HIV co-treatment [PDF]

, 2013
TB and HIV are immuno-pathologically interacting epidemic infectious diseases affecting the lives of millions globally & sub-Saharan African region accounts the highest burden of both diseases.
Habtewolde Eyakem, Abiy
core   +1 more source

Optimization of HIV and tuberculosis co-treatment in Tanzania : drug-drug interactions and clinical outcomes [PDF]

, 2013
Background: Sub-Saharan Africa has been greatly affected by the HIV epidemic, with an estimated 23.5 million people living with HIV/AIDS (PLWHA) residing within this region by the end of 2011, being the leading course of morbidity and mortality. Tanzania
Mugusi, Sabina
core   +1 more source